Threshold Pharmaceuticals Enters Into Definitive

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Threshold Pharmaceuticals Enters Into Definitive Co-Promotion Agreement for Evofosfamide With Merck KGaA, Darmstadt, Germany

SOUTH SAN FRANCISCO, CA--(Marketwired - Nov 18, 2015) - Threshold Pharmaceuticals, Inc. ( NASDAQ : THLD ) today announced that it finalized a definitive Co-Promotion Agreement for evofosfamide with Merck KGaA, Darmstadt, Germany pursuant to the companies' License and Co-Development Agreement entered into on February 2, 2012. Under the terms of the License and Co-Development Agreement, Threshold may co-promote evofosfamide (previously known as TH-302) in the U.S. subject to Food and Drug Administration (FDA) approval of evofosfamide. Evofosfamide is Threshold's investigational hypoxia-activated prodrug, which is currently the subject of two fully enrolled Phase 3 clinical trials in advanced soft tissue sarcoma and advanced pancreatic cancer for which Threshold expects to announce top-line data around the end of 2015.

Under the commercial leadership of Merck KGaA, Darmstadt, Germany, the terms of the License and Co-Development Agreement give Threshold the right, at its own cost, to field and be responsible for its own sales force in collaboration with Merck KGaA, Darmstadt, Germany's sales force in the U.S. pursuant to the terms of the new Co-promotion Agreement. Merck KGaA, Darmstadt, Germany remains responsible for all other commercial and medical affairs functions associated with the launch and promotion of evofosfamide. The development milestone payment and royalty payment portions of the License and Co-Commercialization Agreement remain the same. To date Threshold has received upfront and milestone payments of $110 million and can earn additional potential milestone payments of up to $440 million. 

"We are pleased to have reached an agreement with our partner Merck KGaA, Darmstadt, Germany on definitive terms for our option to co-promote evofosfamide in the U.S.," said Barry Selick, Ph.D., Chief Executive Officer at Threshold. "The ability to co-promote and field a sales force represents one of two key options allowing Threshold to participate in the commercial phase of evofosfamide's lifecycle should it receive FDA approval. Importantly, the license agreement also provides us with an option to co-commercialize evofosfamide in the U.S., depending upon achieving certain milestones, which would allow us to share in up to fifty percent of the profits from the sale of the drug. Threshold is well positioned to integrate a commercial arm to its oncology discovery and development organization."

About Evofosfamide Evofosfamide (previously known as TH-302) is an investigational hypoxia-activated prodrug that is thought to be activated under severe hypoxic tumor conditions, a feature of many solid tumors. Areas of low oxygen levels (hypoxia) in solid tumors are due to insufficient blood vessel supply. Similarly, the bone marrow of patients with hematological malignancies has also been shown, in some cases, to be severely hypoxic. Evofosfamide is currently in two Phase 3 trials, both of which are fully recruited: one in combination with doxorubicin versus doxorubicin alone in patients with locally advanced unresectable or metastatic soft tissue sarcoma (STS) (the TH-CR-406 trial), and the other in combination with gemcitabine versus gemcitabine and placebo in patients with locally advanced unresectable or metastatic pancreatic cancer (the MAESTRO trial). Top-line data for both trials are expected around the end of 2015. Both Phase 3 trials are being conducted under Special Protocol Assessment (SPA) agreements with the FDA. The FDA and the European Commission have granted evofosfamide Orphan Drug designation for the treatment of STS and pancreatic cancer. The FDA has also granted Fast Track designation for evofosfamide for both STS and pancreatic cancer. Evofosfamide is also being investigated in a Phase 2 trial designed to support registration for the treatment of non-squamous non-small cell lung cancer, and in earlier-stage clinical trials of other solid tumors and hematological malignancies.

Threshold has a global license and co-development agreement for evofosfamide with Merck KGaA, Darmstadt, Germany, which includes an option for Threshold to co-commercialize in the U.S.

About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting tumor hypoxia, the low oxygen condition found in the microenvironments of most solid tumors as well as the bone marrows of some patients with hematologic malignancies. This approach offers broad potential to treat a variety of cancers. By selectively targeting tumor cells, we are building a pipeline of drugs that hold promise to be more effective and less toxic to healthy tissues than conventional anticancer drugs. For additional information, please visit our website ( www.thresholdpharm.com ).

Forward-Looking Statements Except for statements of historical fact, the statements in this press release are forward-looking statements, including statements regarding the benefits of the agreement between Threshold and Merck, including future financial and operating results, the combined plans, objectives, expectations and intentions of Threshold and Merck, anticipated development activities and clinical development outlook related to company- and Merck KGaA, Darmstadt, Germany-sponsored clinical trials for evofosfamide, including the expected efficient execution and expected timing of and availability of the top-line results from the ongoing evofosfamide Phase 3 clinical trials the potential therapeutic uses and benefits of evofosfamide. These statements involve risks and uncertainties that can cause actual results to differ materially from those in such forward-looking statements. Potential risks and uncertainties include, but are not limited to: the possibility that FDA approval of evofosfamide may not be realized or may not be realized within the expected tie period, due to, among other things, the impact of pharmaceutical industry regulation, health policies, and pending legislation that could affect the pharmaceutical industry, the ability of Threshold and Merck KGaA, Darmstadt, Germany, to enroll or complete evofosfamide clinical trials; the time and expense required to conduct such clinical trials and analyze data; issues arising in the regulatory or manufacturing process and the results of such clinical trials (including product safety issues and efficacy results); the risk that the final data from ongoing trials may be materially different from the preliminary data that Threshold has reported; risks related to Threshold's dependence on its collaborative relationship with Merck KGaA, Darmstadt, Germany, including its dependence on decisions by Merck KGaA, Darmstadt, Germany regarding the amount and timing of resource expenditures for the development of evofosfamide, including the commencement of additional clinical trials; and Threshold's need for and the availability of resources to develop evofosfamide and to support Threshold's operations. Further information regarding these and other risks is included under the heading "Risk Factors" in Threshold's Quarterly Report on Form 10-Q, which has been filed with the Securities and Exchange Commission on November 2, 2015 and is available from the SEC's website ( www.sec.gov ) and on our website ( www.thresholdpharm.com ) under the heading "Investors." We undertake no duty to update any forward-looking statement made in this news release.

Contact Laura Hansen, Ph.D. Senior Director, Corporate Communications Phone: 650-474-8206 E-mail: lhansen@thresholdpharm.com

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Avelo Tests Loyalty Math With WeSalute Fare Discounts

Updated Category News Views 237

Airline discounts can look like generosity until the load factor starts talking back. Avelo Airlines has joined WeSalute with fare discounts for active-duty military members, veterans, first responders, nurses, medical professionals, public servants, teachers and eligible family members. It is a sensible move for a young carrier built around smaller airports and lower...

Continue Reading
ZTO's Pricing Muscle Shows Up in Third-Quarter Results

Updated Category News Views 136

Ten billion parcels can hide plenty of ugly economics, but ZTO's third quarter does not look like a volume-at-any-cost stunt. The company moved 10.241 billion parcels, up 7.0% from a year earlier, and says that outpaced the industry by 4.1 percentage points. More importantly, revenue climbed 21.0% to RMB14.36 billion while adjusted net income reached RMB2.57 billion. That...

Continue Reading
GALLS Honors Service With Lexington Hall of Fame Wall

Updated Category News Views 86

A headquarters wall can say more about a company than another polished mission statement ever will. On November 17, 2026, GALLS® unveiled the National Law Enforcement Officer Hall of Fame Wall at its Lexington, Kentucky, corporate headquarters, displaying portraits of every past inductee into the National Law Enforcement Officer Hall of Fame. Recognition, made permanent...

Continue Reading
Floating Solar Gets a Serious Test in Central New York

Updated Category News Views 86

A flooded quarry pit outside Cortlandville is getting a second career, and that is more interesting than another solar announcement draped across empty acreage. Third Pillar Power has started construction on Crown City Solar at Suit-Kote Corporation's active Polkville Crushed Stone Facility, pairing a working mine, asphalt plant, and storage terminal with what the...

Continue Reading
Exiger's CEO Honored for Military Support Excellence

Updated Category News Views 58

Recognizing Civilian and Military Leadership When you hear "recognition in the military sector," it isn't just a pat on the back. It's a whole parade of brass hats and high-flyers giving their nods. So, November 10th wasn't just any regular day—Brandon Daniels, CEO of Exiger, gets a shiny, prestigious Five-Star Award for his "extraordinary support" of our military...

Continue Reading
Sola's 11-Step Push Makes Salon Ownership Less Blind

Updated Category News Views 115

A pristine studio does not pay rent by itself. That is the uncomfortable little truth sitting underneath Sola Salons’ new 11-step roadmap for beauty professionals considering salon-suite ownership. The company is telling stylists, estheticians, nail technicians, massage therapists, and other independent operators to treat the move from commission work to ownership like...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 32

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
Voltage Energy's Microgrid Launches at RE+ 2026

Updated Category News Views 147

Voltage Energy Unveils New Power Systems In the swirling chaos of energy innovation, Voltage Energy is trying to carve its path at the heart of RE+ 2026. Out in Las Vegas, amidst the buzz of renewable energy tech, they introduced their Microgrid System (MGS) along with two new electrical balance of system (EBOS) products—the Load Break Disconnect Box (LBD) and Combiner...

Continue Reading
Stand Out For Good Makes a Bold Michigan Avenue Bet

Updated Category News Views 183

A six-floor retail commitment lands with a thud Stand Out For Good is taking on roughly 51,079 square feet at 669 North Michigan Avenue, and nobody should mistake that for a casual expansion. Six levels on Chicago's Magnificent Mile is a proper declaration of intent, especially in a retail district that has endured plenty of empty-window handwringing and big-brand churn....

Continue Reading
Medical School Rejections Carry a Steep Price Tag Too

Updated Category News Views 107

A rejection letter can turn into a remarkably expensive piece of paper. BeMo Academic Consulting's new Medical School Admissions Trends Report argues that the damage from missing medical-school admission goes far beyond bruised confidence: applicants can spend thousands chasing another cycle, lose time entering practice, and, if they never get in, forgo what the report...

Continue Reading

Top 5 Most Recently Viewed Articles

Coway's Inverter Dehumidifier 23L Triumphs at Global Design Awards

Updated Category News Views 208

Inverter Dehumidifier 23L Wins Recognition at Good Design Awards - The Inverter Dehumidifier 23L gains accolades for its compact design and user-friendly features at the Good Design Awards 2025. - This recent achievement cements Coway's status as a leading player in global design, recognized by all four major awards this year. Coway's Prestigious Award Recognition Hosted...

Continue Reading
Veru's Enobosarm & Semaglutide: A New Era in Weight Loss Safety

Updated Category News Views 314

Positive Safety Profile from Veru's Clinical Study Veru Inc. (NASDAQ: VERU), a trailblazer in biopharmaceuticals, recently revealed exciting topline safety results from its Phase 2b QUALITY clinical study. This trial examined the combination of enobosarm and semaglutide, uncovering significant advantages in safety and efficacy compared to semaglutide alone. Understanding...

Continue Reading
How a $1000 Investment in REV Group Can Grow Over Time

Updated Category News Views 180

Understanding REV Group's Market Performance REV Group (NYSE: REVG) has demonstrated impressive performance in the stock market over the past five years. This company has not only outperformed the broader market, but it has done so by a remarkable 29.45% on an annualized basis, resulting in an average annual return of 42.83%. With a market capitalization reaching...

Continue Reading
Castellum's GTMR Achieves Key CMMI Level 3 Milestone

Updated Category News Views 172

Castellum's GTMR Achieves Key CMMI Level 3 Milestone Castellum, Inc. (NYSE-American: CTM) has exciting news to share, as it announces its subsidiary, Global Technology and Management Resources, Inc. (GTMR), has achieved a significant milestone by obtaining a Level 3 appraisal under ISACA’s Capability Maturity Model Integration (CMMI). This recognition highlights GTMR's...

Continue Reading
Discovering Nature Close Up: The MicroCam X1 Launch

Updated Category News Views 162

Introducing the MicroCam X1 by Littpopo Littpopo, an innovative brand dedicated to exploration technology, has launched the MicroCam X1, a remarkable pocket microscope camera now live on a crowdfunding platform. This unique device combines a powerful 400X microscope with a 4K camera, making it an essential tool for educators, content creators, families, and adventurers...

Continue Reading